Results 21 to 30 of about 4,843 (156)

Comparative Effects of Emerging Lp(a)-Lowering Agents and PCSK9-Directed Therapies on Lipoprotein(a): A Network Meta-Analysis of Randomised Clinical Trials. [PDF]

Diabetes Obes Metab
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Zayed JA, Al-Awamleh NA, Hamad M, Hdaib MIM, Ayesh H.   +4 more
europepmc   +2 more sources

Alirocumab effect on preventing periprocedural ischaemic events in coronary heart disease patients undergoing coronary stenting (APPEASE trial): study protocol of a multicentre, open-label, randomised controlled trial

BMJ Open, 2023
Introduction Percutaneous coronary intervention (PCI)-related myocardial infarction (type 4a MI) and major periprocedural myocardial injury have been demonstrated leading to poor prognosis of patients with coronary heart disease (CHD) undergoing elective
Yang Chen, Suhua Li, Lianxiong Yuan, Zhenyu Xiong, Jinlai Liu, Xiaoxian Qian, Longgen Xiong, Leile Tang, Zhuoshan Huang, Xiaodong Zhuang, Shaozhao Zhang, Yiquan Huang, Aiwen Lin, Odong Christopher, Bingyuan Wu, Yesheng Ling, Qiang Jie, Xinxue Liao   +17 more
doaj   +1 more source

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study

Frontiers in Cardiovascular Medicine, 2023
BackgroundDespite better accessibility of the effective lipid-lowering therapies, only about 20% of patients at very high cardiovascular risk achieve the low-density lipoprotein cholesterol (LDL-C) goals.
Maciej Banach, Maciej Banach, Maciej Banach, Maciej Banach, Joanna Lewek, Joanna Lewek, Kaja Pol, Daniel Rabczenko, Serban M. Balanescu, Vladimir Blaha, Richard Ceska, Piotr Jankowski, Piotr Jankowski, Stanisław Surma, Genovefa Kolovou, Evangelos Liberopoulos, Florin Mitu, Magda Mitu, Franjo Husam Naji, Gyorgy Paragh, Magdalena Popławska, Michal Vrablik, Daniel Pella   +22 more
doaj   +1 more source

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:Results of a 24week, double-blind, randomized Phase 3 trial [PDF]

, 2014
Background:Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy. Methods In a Phase 3, randomized, double-blind, double-dummy
Merlet, Laurence, Robinson, Jennifer G., Kastelein, John J.P., Roth, Eli M., Colhoun, Helen M., Pordy, Robert, Taskinen, Marja-Riitta, Ginsberg, Henry N., Kastelein, John J. P., Baccara-Dinet, Marie T.   +9 more
core   +1 more source

Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease

Open Heart, 2021
Background Atherosclerotic cardiovascular disease is the leading cause of death and disability in the Western world.Objective To characterise adults with confirmed coronary heart disease (CHD) and primary heterozygous familial or non-familial ...
Peter Bramlage, Daniel Steffens, Julia Müller, Cornelia Dorn, W Dieter Paar, Celine Scheeff, Mario Kasner, U Rauch-Kröhnert   +7 more
doaj   +1 more source

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundAlirocumab undergoes target‐mediated clearance via binding of proprotein convertase subtilisin/kexin type 9 (PCSK9). Statins increase PCSK9 levels; the effects of nonstatin lipid‐lowering therapies are unclear.
Jacques Rey, Franck Poitiers, Tobias Paehler, Aurélie Brunet, A. Thomas DiCioccio, Christopher P. Cannon, Howard K. Surks, Jean‐Louis Pinquier, Corinne Hanotin, William J. Sasiela   +9 more
doaj   +1 more source

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. [PDF]

, 2019
BACKGROUND: Lowering of atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the risk of ischemic stroke. However, concerns have been raised about very low LDL-C levels and a potential increased risk of hemorrhagic ...
For the ODYSSEY OUTCOMES Investigators, Szarek, M., Goodman, Shaun G, Kim, YU, Vera A. Bittner, Roe, MT, Roe, Matthew T., Schwartz, Gregory G., Pordy, Robert, Gregory G. Schwartz, Schwart, GG, Yong-Un Kim, Zeiher, AM, Drexel, Heinz, Bhatt, Deepak L., Laurien E. Zijlstra, Zeiher, Andreas M, Steg, PG, Reiner, Zeljko, White, Harvey D, Pordy, R, Philippe Gabriel Steg, Deepak L. Bhatt, Tse, Hung Fat, Schwartz, Gregory G, Kim, Yong-Un, Schwartz, G.G., Reiner, Ž, Goodman, SG, Bhatt, DL, Zeiher, A.M., White, HD, Zeiher, Andreas M., Zijlstra, Laurien E, Diaz, R., Drexel, H., Harvey D. White, Jukema, J.W., Tse, H.F., Rafael Diaz, Drexel, H, Szarek, Michael, Andreas M. Zeiher, Goodman, S.G., Jukema, J. Wouter, Hung-Fat Tse, Steg, Philippe Gabriel, Jukema, J Wouter, Goodman, Shaun G., Valdovinos, P.C.M., Tse, Hung-Fat, J. Wouter Jukema, Diaz, Rafael, ODYSSEY OUTCOMES Investigators, Kim, Y.U., Pablo Carlos Montenegro Valdovinos, Diaz, R, Bhatt, Deepak L, White, Harvey D., Michael Szarek, Roe, M.T., Montenegro Valdovinos, Pablo Carlos, Bittner, Vera A., Reiner, Z., Matthew T. Roe, Bittner, VA, Zijlstra, Laurien E., Tse, HF, Pordy, R., Bhatt, D.L., Željko Reiner, Valdovinos, Pablo Carlos Montenegro, Robert Pordy, Bittner, Vera A, Zijlstra, LE, White, H.D., Jukema, JW, Steg, P.G., Shaun G. Goodman, Bittner, V.A., Roe, Matthew T, Zijlstra, L.E., Heinz Drexel, Valdovinos, PCM, Szarek, M   +84 more
core   +2 more sources

Early effects of PCSK9 inhibitors: evolocumab versus alirocumab [PDF]

Kosin Medical Journal
Background The significance of risk modification in patients with acute coronary syndrome (ACS) is well recognized; however, the optimal timing for adminstering PCSK9 inhibitors remains unclear. Additionally, the lipid-lowering efficacy of evolocumab and
Su-Hyun Bae, Bong-Joon Kim, Soo-Jin Kim, Sung-Il Im, Hyun-Su Kim, Jung-Ho Heo   +5 more
doaj   +1 more source

Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study

Biomedicines, 2022
Background: PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich ...
Thomas Metzner, Deborah R. Leitner, Karin Mellitzer, Andrea Beck, Harald Sourij, Tatjana Stojakovic, Gernot Reishofer, Winfried März, Ulf Landmesser, Hubert Scharnagl, Hermann Toplak, Günther Silbernagel   +11 more
doaj   +1 more source

Effect of Alirocumab on Mortality After Acute Coronary Syndromes [PDF]

, 2019
Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death.
Kollaborációs szervezet: ODYSSEY OUTCOMES Committees and Investigators, Brégeault Marie-France, Bhatt Deepak L, Ungi Imre, Merkely Béla Péter, Bittner Vera A, Horváth Iván, Steg Philippe Gabriel, Szarek Michael   +8 more
core   +1 more source